Minimally Displaced Femoral Neck Fracture Pilot Study
Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Jul 11, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The "Minimally Displaced Femoral Neck Fracture Pilot Study" is a research project aimed at understanding the best ways to treat a specific type of hip fracture in older adults. This study is looking for patients aged 60 and older who have experienced a low-energy fracture of the femoral neck, which often happens from a simple fall. Participants will be randomly assigned to one of two treatment options: hip arthroplasty (joint replacement) or internal fixation (using screws or plates to hold the bone together). The goal is to gather information that will help design a larger, more definitive study in the future.
To be eligible, patients must be able to walk at least 10 feet before their injury and have a specific type of fracture confirmed by medical imaging. They should also be in good enough health for surgery, and consent must be obtained from them or a family member. Throughout the year following their treatment, participants will be monitored to see how well they recover. This study is currently recruiting participants and aims to improve care for older adults with this common injury.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 60 years of age or older.
- • Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging (MRI).
- • Minimally displaced fracture that could be, in the judgment of the attending surgeon, optimally managed with either arthroplasty or in situ internal fixation without reduction.
- • Low energy injury mechanism defined as a fall from standing height.
- • Informed consent obtained from patient or proxy.
- • Surgeons with expertise in total hip arthroplasty, hemiarthroplasty, and internal fixation are available to perform surgery. Note: Surgeons do not need to be experts in all techniques.
- Exclusion Criteria:
- • Unable to ambulate 10 feet pre-injury with any assistance.
- • Associated lower extremity injury that prevents post-operative weightbearing.
- • Retained hardware around the hip that precludes either study treatment.
- • Infection around the hip (soft tissue or bone).
- • Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
- • Patient is too ill, in the judgement of the attending surgeon, for internal fixation.
- • Patient is too ill, in the judgement of the attending surgeon, for arthroplasty.
- • Unable to obtain informed consent due to language barriers.
- • Problems, in the judgment of study personnel, with maintaining follow-up with the patient.
- • Currently enrolled in a study that does not permit co-enrollment.
- • Prior enrollment in the trial.
- • Other reason to exclude the patient, as approved by the Methods Centre.
About University Of Maryland, Baltimore
The University of Maryland, Baltimore (UMB) is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, UMB leverages its extensive resources and expertise across various disciplines, including medicine, pharmacy, nursing, and social work, to contribute to groundbreaking discoveries and improve patient outcomes. Committed to ethical research practices and collaboration, UMB fosters an environment that promotes the translation of scientific knowledge into real-world applications, ultimately enhancing the well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Boston, Massachusetts, United States
Lebanon, New Hampshire, United States
Barcelona, , Spain
Gainesville, Florida, United States
London, Ontario, Canada
Hamilton, Ontario, Canada
Baltimore, Maryland, United States
Falls Church, Virginia, United States
Los Angeles, California, United States
Largo, Maryland, United States
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Gerard Slobogean, MD
Principal Investigator
University of Maryland, Baltimore
Sheila Sprague, PhD
Principal Investigator
McMaster University
Joseph Patterson, MD
Principal Investigator
University of Southern California
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported